Vale Biolabs Raises €164K to Advance Brain Disease Research

The big picture: Biotech startup Vale Biolabs has secured €164,000 from Venture Kick to further develop its platform for studying brain diseases and evaluating potential treatments. The company combines lab-grown human brain tissue, automation, and predictive AI to enhance understanding of drug responses and support new therapy development.

Why it matters:

• Preclinical challenges: Developing treatments for neurological disorders is difficult, with preclinical research heavily relying on animal testing. Differences between animal and human biology often lead to drug failures in clinical trials, increasing costs and delaying new therapies.
• Human-relevant models: Vale Biolabs addresses this by developing standardized human brain organoids—miniature tissue models that reproduce key characteristics of the human brain—to provide more accurate insights into drug performance.
• Accelerated development: By enabling drug developers to test treatments on human brain tissue earlier, the platform aims to identify promising therapies and potential failures before they reach costly clinical trials, potentially reducing development costs and speeding up treatment introductions.

How it works:

• Organoid platform: The company creates standardized human brain organoids, which are miniature tissue models designed to mimic aspects of the human brain’s structure and function.
• Automated monitoring: Using automation, Vale Biolabs continuously monitors changes in these organoid models, analyzing their structure, activity, and molecular responses both before and after exposure to potential treatments.
• Predictive AI: The extensive data collected from these experiments is then used to train predictive AI models, supporting research into brain development, neurodegenerative diseases like Alzheimer’s and Parkinson’s, and healthy brain aging.

The catch: The effectiveness of organoid-based platforms like Vale Biolabs’ hinges on their ability to accurately replicate the complex in-vivo brain environment and gain widespread acceptance within a research landscape that still heavily relies on traditional preclinical models. Broader adoption will require robust validation against existing methods.

Key Facts

• Company: Vale Biolabs
• Amount: €164K
• Round: Seed
• Investor: Venture Kick (lead)
• Founders: Ilaria Incaviglia, Angeliki Damilou, Daniel Medina Cano, Theodoulos Rodosthenous
• Announced: 2026-11-09
• Sector: Neuroscience Drug Discovery